Tibra Equities Europe Ltd Invests $8.05 Million in Merck & Co., Inc. (NYSE:MRK)

Tibra Equities Europe Ltd bought a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 96,800 shares of the company’s stock, valued at approximately $8,051,000. Merck & Co., Inc. accounts for 0.8% of Tibra Equities Europe Ltd’s investment portfolio, making the stock its 26th biggest position.

Several other large investors have also recently modified their holdings of MRK. PRW Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $41,000. Aspire Private Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $55,000. Financial Gravity Companies Inc. purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $66,000. Mark Sheptoff Financial Planning LLC grew its holdings in shares of Merck & Co., Inc. by 150.0% during the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the company’s stock worth $76,000 after purchasing an additional 600 shares during the period. Finally, Vestor Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $77,000. Institutional investors and hedge funds own 75.17% of the company’s stock.

In other Merck & Co., Inc. news, EVP Robert M. Davis sold 192,572 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $82.38, for a total value of $15,864,081.36. Following the transaction, the executive vice president now directly owns 330,232 shares of the company’s stock, valued at approximately $27,204,512.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Merck & Co., Inc. bought 4,121,683 shares of the business’s stock in a transaction on Monday, April 8th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $65,946,928.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 445,308 shares of company stock worth $36,421,320. 0.27% of the stock is currently owned by corporate insiders.

Several equities analysts recently commented on the company. JPMorgan Chase & Co. boosted their price target on Merck & Co., Inc. from $90.00 to $93.00 and gave the stock an “overweight” rating in a research report on Friday. ValuEngine lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Thursday, April 18th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research report on Monday, April 1st. Goldman Sachs Group assumed coverage on Merck & Co., Inc. in a research report on Tuesday, May 28th. They set a “neutral” rating and a $85.00 price target on the stock. Finally, BMO Capital Markets reissued a “hold” rating on shares of Merck & Co., Inc. in a research report on Tuesday, February 19th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $83.79.

Merck & Co., Inc. stock traded down $0.02 during midday trading on Friday, hitting $82.88. 2,426,372 shares of the company were exchanged, compared to its average volume of 8,654,134. The firm has a market capitalization of $215.52 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 1.99 and a beta of 0.55. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.06 and a current ratio of 1.37. Merck & Co., Inc. has a fifty-two week low of $59.80 and a fifty-two week high of $84.27.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, April 30th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.17. Merck & Co., Inc. had a return on equity of 39.85% and a net margin of 19.50%. The company had revenue of $10.82 billion for the quarter, compared to analyst estimates of $10.45 billion. During the same period in the prior year, the company posted $1.05 EPS. Merck & Co., Inc.’s quarterly revenue was up 7.8% on a year-over-year basis. On average, analysts forecast that Merck & Co., Inc. will post 4.72 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date of this dividend is Friday, June 14th. Merck & Co., Inc.’s payout ratio is 50.69%.

COPYRIGHT VIOLATION NOTICE: “Tibra Equities Europe Ltd Invests $8.05 Million in Merck & Co., Inc. (NYSE:MRK)” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.chaffeybreeze.com/2019/06/14/tibra-equities-europe-ltd-invests-8-05-million-in-merck-co-inc-nysemrk.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Day Trading – Risk Worth the Reward?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.